TEVA vs. UTHR: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at TEVA and UTHR, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
TEVA trades as an American Depositary Receipt (ADR), offering U.S. investors a convenient way to access its foreign-listed shares. In contrast, UTHR is a standard domestic listing.
| Symbol | TEVA | UTHR |
|---|---|---|
| Company Name | Teva Pharmaceutical Industries Limited | United Therapeutics Corporation |
| Country | Israel | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Pharmaceuticals | Biotechnology |
| Market Capitalization | 23.47 billion USD | 20.30 billion USD |
| Exchange | NYSE | NasdaqGS |
| Listing Date | February 16, 1982 | June 17, 1999 |
| Security Type | ADR | Common Stock |
Historical Performance
This chart compares the performance of TEVA and UTHR by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | TEVA | UTHR |
|---|---|---|
| 5-Day Price Return | 8.05% | 1.24% |
| 13-Week Price Return | 17.76% | 49.36% |
| 26-Week Price Return | 14.27% | 46.06% |
| 52-Week Price Return | 11.38% | 28.32% |
| Month-to-Date Return | 4.21% | 7.09% |
| Year-to-Date Return | -17.16% | 27.23% |
| 10-Day Avg. Volume | 1.73M | 0.83M |
| 3-Month Avg. Volume | 1.86M | 0.75M |
| 3-Month Volatility | 28.95% | 72.74% |
| Beta | -0.38 | 0.87 |
Profitability
Return on Equity (TTM)
TEVA
-2.58%
Pharmaceuticals Industry
- Max
- 38.59%
- Q3
- 19.84%
- Median
- 11.85%
- Q1
- 5.40%
- Min
- -10.91%
TEVA has a negative Return on Equity of -2.58%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
UTHR
18.73%
Biotechnology Industry
- Max
- 97.92%
- Q3
- 11.99%
- Median
- -19.30%
- Q1
- -51.29%
- Min
- -132.03%
In the upper quartile for the Biotechnology industry, UTHR’s Return on Equity of 18.73% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
Net Profit Margin (TTM)
TEVA
-0.95%
Pharmaceuticals Industry
- Max
- 40.67%
- Q3
- 19.07%
- Median
- 12.31%
- Q1
- 4.50%
- Min
- -9.91%
TEVA has a negative Net Profit Margin of -0.95%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
UTHR
40.36%
Biotechnology Industry
- Max
- 73.34%
- Q3
- 18.98%
- Median
- -12.96%
- Q1
- -105.72%
- Min
- -259.82%
A Net Profit Margin of 40.36% places UTHR in the upper quartile for the Biotechnology industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin (TTM)
TEVA
5.38%
Pharmaceuticals Industry
- Max
- 45.78%
- Q3
- 23.14%
- Median
- 16.68%
- Q1
- 7.98%
- Min
- -7.13%
TEVA’s Operating Profit Margin of 5.38% is in the lower quartile for the Pharmaceuticals industry. This indicates weaker profitability from core operations, which may stem from inefficiencies or competitive pressures on pricing.
UTHR
47.05%
Biotechnology Industry
- Max
- 78.85%
- Q3
- 21.90%
- Median
- -13.30%
- Q1
- -109.94%
- Min
- -278.10%
An Operating Profit Margin of 47.05% places UTHR in the upper quartile for the Biotechnology industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
| Symbol | TEVA | UTHR |
|---|---|---|
| Return on Equity (TTM) | -2.58% | 18.73% |
| Return on Assets (TTM) | -0.40% | 16.48% |
| Net Profit Margin (TTM) | -0.95% | 40.36% |
| Operating Profit Margin (TTM) | 5.38% | 47.05% |
| Gross Profit Margin (TTM) | 50.88% | 88.98% |
Financial Strength
Current Ratio (MRQ)
TEVA
1.06
Pharmaceuticals Industry
- Max
- 4.65
- Q3
- 2.64
- Median
- 1.85
- Q1
- 1.26
- Min
- 0.78
TEVA’s Current Ratio of 1.06 falls into the lower quartile for the Pharmaceuticals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
UTHR
7.26
Biotechnology Industry
- Max
- 16.97
- Q3
- 8.39
- Median
- 4.11
- Q1
- 2.64
- Min
- 0.74
UTHR’s Current Ratio of 7.26 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
TEVA
2.52
Pharmaceuticals Industry
- Max
- 1.75
- Q3
- 0.82
- Median
- 0.35
- Q1
- 0.13
- Min
- 0.00
With a Debt-to-Equity Ratio of 2.52, TEVA operates with exceptionally high leverage compared to the Pharmaceuticals industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.
UTHR
0.00
Biotechnology Industry
- Max
- 1.92
- Q3
- 0.79
- Median
- 0.12
- Q1
- 0.00
- Min
- 0.00
UTHR’s Debt-to-Equity Ratio of 0.00 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
TEVA
-0.38
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 43.60
- Median
- 9.83
- Q1
- 2.37
- Min
- -42.71
TEVA has a negative Interest Coverage Ratio of -0.38. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
UTHR
42.15
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.03
- Median
- -9.59
- Q1
- -65.05
- Min
- -163.11
UTHR’s Interest Coverage Ratio of 42.15 is in the upper quartile for the Biotechnology industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
Financial Strength at a Glance
| Symbol | TEVA | UTHR |
|---|---|---|
| Current Ratio (MRQ) | 1.06 | 7.26 |
| Quick Ratio (MRQ) | 0.68 | 6.94 |
| Debt-to-Equity Ratio (MRQ) | 2.52 | 0.00 |
| Interest Coverage Ratio (TTM) | -0.38 | 42.15 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
TEVA
0.00%
Pharmaceuticals Industry
- Max
- 7.14%
- Q3
- 3.45%
- Median
- 2.17%
- Q1
- 0.33%
- Min
- 0.00%
TEVA currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
UTHR
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
UTHR currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
TEVA
0.00%
Pharmaceuticals Industry
- Max
- 199.58%
- Q3
- 97.17%
- Median
- 53.47%
- Q1
- 22.97%
- Min
- 0.00%
TEVA has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
UTHR
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
UTHR has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | TEVA | UTHR |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
TEVA
--
Pharmaceuticals Industry
- Max
- 45.19
- Q3
- 27.91
- Median
- 20.59
- Q1
- 15.08
- Min
- 3.79
P/E Ratio data for TEVA is currently unavailable.
UTHR
16.56
Biotechnology Industry
- Max
- 40.44
- Q3
- 39.37
- Median
- 22.12
- Q1
- 15.76
- Min
- 3.48
UTHR’s P/E Ratio of 16.56 is within the middle range for the Biotechnology industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Price-to-Sales Ratio (TTM)
TEVA
1.40
Pharmaceuticals Industry
- Max
- 8.87
- Q3
- 4.56
- Median
- 2.14
- Q1
- 1.58
- Min
- 0.11
In the lower quartile for the Pharmaceuticals industry, TEVA’s P/S Ratio of 1.40 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
UTHR
6.68
Biotechnology Industry
- Max
- 92.67
- Q3
- 41.36
- Median
- 8.45
- Q1
- 4.46
- Min
- 0.97
UTHR’s P/S Ratio of 6.68 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio (MRQ)
TEVA
2.91
Pharmaceuticals Industry
- Max
- 9.78
- Q3
- 4.99
- Median
- 2.48
- Q1
- 1.53
- Min
- 0.59
TEVA’s P/B Ratio of 2.91 is within the conventional range for the Pharmaceuticals industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
UTHR
1.81
Biotechnology Industry
- Max
- 22.72
- Q3
- 10.68
- Median
- 4.55
- Q1
- 2.44
- Min
- 0.59
UTHR’s P/B Ratio of 1.81 is in the lower quartile for the Biotechnology industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
Valuation at a Glance
| Symbol | TEVA | UTHR |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | -- | 16.56 |
| Price-to-Sales Ratio (TTM) | 1.40 | 6.68 |
| Price-to-Book Ratio (MRQ) | 2.91 | 1.81 |
| Price-to-Free Cash Flow Ratio (TTM) | 20.68 | 19.20 |